Last reviewed · How we verify

Antimoniate of N-methylglucamine

University of Brasilia · FDA-approved active Small molecule

Antimoniate of N-methylglucamine is a pentavalent antimony compound that kills Leishmania parasites by disrupting their metabolism and energy production.

Antimoniate of N-methylglucamine is a pentavalent antimony compound that kills Leishmania parasites by disrupting their metabolism and energy production. Used for Visceral leishmaniasis, Cutaneous leishmaniasis, Mucocutaneous leishmaniasis.

At a glance

Generic nameAntimoniate of N-methylglucamine
Also known asGlucantime
SponsorUniversity of Brasilia
Drug classAntiparasitic agent
TargetLeishmania glycolytic enzymes and mitochondrial function
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

The drug works by penetrating Leishmania parasites and interfering with their glycolytic enzymes and mitochondrial function, leading to parasite death. Pentavalent antimony compounds are reduced to trivalent antimony within the parasite, which then inhibits key metabolic pathways essential for parasite survival. This mechanism makes it effective against various forms of leishmaniasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: